Ciprofloxacin: Clinical Overview
Indications
Ciprofloxacin is FDA-approved for a broad range of bacterial infections in adults, but should be reserved as a second-line agent in most cases due to resistance concerns and adverse effects. 1
Adult Indications (FDA-Approved):
- Urinary tract infections (UTIs) including complicated UTIs, acute uncomplicated cystitis, chronic bacterial prostatitis
- Respiratory infections: Lower respiratory tract infections, acute sinusitis, acute exacerbations of chronic bronchitis (though NOT first-line for Streptococcus pneumoniae pneumonia)
- Gastrointestinal infections: Infectious diarrhea (E. coli, Campylobacter, Shigella), typhoid fever
- Skin and soft tissue infections
- Bone and joint infections
- Complicated intra-abdominal infections (combined with metronidazole)
- Uncomplicated gonorrhea (single dose)
- Inhalational anthrax post-exposure prophylaxis 1
Pediatric Indications (Limited):
In children 1-17 years, ciprofloxacin is FDA-approved ONLY for complicated UTIs and pyelonephritis due to E. coli, and inhalational anthrax post-exposure. 1 The American Academy of Pediatrics guidelines emphasize that ciprofloxacin should be reserved for situations where typically recommended agents are inappropriate based on susceptibility, allergy, or adverse-event history 2. Fluoroquinolones are NOT first-line in pediatrics due to increased joint-related adverse events. 2, 1
Additional pediatric uses supported by guidelines include:
- Multidrug-resistant tuberculosis (when no alternatives exist)
- Pseudomonas aeruginosa infections requiring oral therapy
- Multidrug-resistant Gram-negative meningitis (when no other options available)
- Neisseria meningitidis carriage eradication (alternative to rifampin) 2
Dosing Regimens
Adult Dosing (Oral):
Standard dosing is 250-750 mg every 12 hours, with duration and dose determined by infection severity and site. 1
| Infection Type | Dose | Frequency | Duration |
|---|---|---|---|
| Uncomplicated UTI | 250 mg | q12h | 3 days |
| Complicated UTI | 500 mg | q12h | 7-14 days |
| Chronic prostatitis | 500 mg | q12h | 28 days |
| Lower respiratory (mild/moderate) | 500 mg | q12h | 7-14 days |
| Lower respiratory (severe) | 750 mg | q12h | 7-14 days |
| Infectious diarrhea | 500 mg | q12h | 5-7 days |
| Typhoid fever | 500 mg | q12h | 10 days |
| Bone/joint infections | 500-750 mg | q12h | ≥4-6 weeks |
| Inhalational anthrax | 500 mg | q12h | 60 days |
| Uncomplicated gonorrhea | 250 mg | Single dose | - |
Critical administration timing: Give at least 2 hours before OR 6 hours after antacids, calcium, iron, zinc, or buffered medications. 1 This is particularly important in pediatric oncology patients with enteral feeding tubes 3.
Renal Dose Adjustment:
- CrCl >50 mL/min: Standard dosing
- CrCl 30-50 mL/min: 250-500 mg q12h
- CrCl 5-29 mL/min: 250-500 mg q18h
- Hemodialysis/peritoneal dialysis: 250-500 mg q24h (after dialysis) 1
Pediatric Dosing:
For complicated UTI/pyelonephritis: 10-20 mg/kg orally every 12 hours (maximum 750 mg/dose). 1 Recent evidence suggests standard dosing (20-30 mg/kg/day) may be insufficient in non-ventilated critically ill children with normal renal function, potentially requiring 15 mg/kg every 8 hours (off-label) 4. For mechanically ventilated children, 10 mg/kg every 12 hours appears adequate. 4
Contraindications
Absolute contraindications: 1
- Hypersensitivity to ciprofloxacin or any quinolone
- Concomitant use with tizanidine (causes severe hypotension and sedation)
Relative contraindications/strong cautions:
- Pediatric use (age <18 years) except for approved indications, due to arthropathy risk 2, 1
- Pregnancy and lactation (not mentioned in pediatric guidelines for non-pregnant women) 2
- History of tendon disorders
- QTc prolongation or concurrent QT-prolonging drugs 5
- Myasthenia gravis (may worsen muscle weakness)
Alternative Therapies
For UTIs:
First-line alternatives in adults: Nitrofurantoin, trimethoprim-sulfamethoxazole (if local resistance <20%), fosfomycin for uncomplicated cystitis. In pediatrics, cephalosporins remain first-line due to increasing TMP-SMX and amoxicillin resistance 2.
For Respiratory Infections:
For community-acquired pneumonia: Macrolides (azithromycin) or respiratory fluoroquinolones (levofloxacin, moxifloxacin) are preferred over ciprofloxacin for S. pneumoniae coverage 1. Levofloxacin has superior activity against S. pneumoniae and Mycoplasma compared to ciprofloxacin 2.
For Gastrointestinal Infections:
Azithromycin is preferred for Campylobacter and traveler's diarrhea in areas with high fluoroquinolone resistance. For typhoid fever, ceftriaxone or azithromycin are alternatives.
For Pediatric Infections:
Cephalosporins (ceftriaxone, cefotaxime, ceftazidime) remain first-line for most serious pediatric infections. Reserve ciprofloxacin for multidrug-resistant organisms or when parenteral therapy must be avoided 2.
Key Clinical Considerations
Resistance patterns: Ciprofloxacin resistance in E. coli ranges from 4-7% in pediatric tertiary centers, but remains <3% overall in children (except cystic fibrosis patients) 2. Resistance develops more readily in Pseudomonas respiratory infections. 6
Drug interactions requiring attention:
- 28.5% interaction rate with acetaminophen, 31.1% with ibuprofen in community settings 5
- Antacids, calcium, iron, zinc significantly reduce absorption
- QTc-prolonging drugs increase arrhythmia risk 5
Adverse events to monitor:
- Tendinitis/tendon rupture (3.97% incidence) 5
- Dysglycemia (hypoglycemia 1.32%, hyperglycemia 0.66%) 5
- QTc prolongation (2.65%) 5
- Joint toxicity in children (though not systematically reported in long-term tuberculosis treatment) 2
Therapeutic drug monitoring: In critically ill patients, standard dosing often fails to achieve AUC/MIC ≥125. Consider initial loading dose of 800 mg in adults or monitoring in patients with altered pharmacokinetics 7.